Cited by 951Schizophrenia research and treatmentCardiac Health and Mental HealthDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 150 of the 152 references it cites were found in a registry or an index.

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

De Hert, M., Dekker, J.M., Wood, D., Kahl, K.G., Holt, R.I.G., Möller, H.-J.·2009·European Psychiatry

DOI 10.1016/j.eurpsy.2009.01.005

Open this paper in CoChat — free account

Abstract

People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes.

Integrity signals

Registry

Crossref · 10.1016/j.eurpsy.2009.01.005

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Obesity and physical activity: A review
Bensimhon, D., Kraus, W. E., & Donahue, M. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.03.005 · Cited by 122
Retracted
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“- Document téléchargé le 23/06/2011 par AS OF EUROPEAN diabetes [78,131].”
Background
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,865
Self-citation
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Diagnosis and Classification of diabetes mellitus
Rossi, G. (2014) · Diapedia.org eBooks · doi:10.14496/dia..20 · Cited by 3,212
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy.
Rozanski, A., Blumenthal, J. A., & Kaplan, J. (1999) · Circulation · doi:10.1161/01.cir.99.16.2192 · Cited by 2,846

Show all 152 references

Research works printed but not linked: 8

10.1176/ajp.2006.163.4.611 · DOI
Scheen, 2008, Traitement neuroleptique et troubles metabolic, Med Mal Metabol, 2, 593
Correll, 2008, Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents, J Clin Psychiatry, 69, 26
Citrome, 2007, Risk-Benefit Analysis of Available Treatments for Schizophrenia, Psychiatric Times, 1, 27
2008, Clinical Practice Guidelines for the prevention and management of diabetes in Canada, Can J Diabetes, 32, S1
Casey, 2004, Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia, J Clin Psychiatry, 65, 4
Henderson, 2005, Schizophrenia and comorbid metabolic disorders, J Clin Psychiatry, 66, 11
Nicol, 2009, Preliminary results of the MEAC study: metabolic effects of antipsychotics in children, Schizophr Bull, 35, 32

Sorted by citations

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citation
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citation
Priority actions for the non-communicable disease crisis
Beaglehole, R., Bonita, R., Horton, R., Adams, C., Alleyne, G., Asaria, P., Baugh, V., Bekedam, H., Billo, N., Casswell, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60393-0 · Cited by 1,615
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Self-citation
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & Binder, M. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,120
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870
Self-citation
Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden
Nordentoft, M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Laursen, T. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055176 · Cited by 778
Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London
Chang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019590 · Cited by 714
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Self-citation
EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH)
Stubbs, B., Vancampfort, D., Hallgren, M., Firth, J., Veronese, N., Solmi, M., Brand, S., Cordes, J., Malchow, B., Gerber, M., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.07.004 · Cited by 697
Self-citation
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Self-citation
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 698
Review: Inequalities in healthcare provision for people with severe mental illness
Lawrence, D., & Kisely, S. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382058 · Cited by 649
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 664
Self-citation
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014
Hayes, J. F., Marston, L., Walters, K., King, M. B., & Osborn, D. P. J. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.117.202606 · Cited by 451
Social jetlag, chronotype, and cardiometabolic risk
Wong, P. M., Hasler, B. P., Kamarck, T. W., Muldoon, M. F., & Manuck, S. B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2923 · Cited by 444
Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators
Vancampfort, D., Vansteelandt, K., Correll, C. U., Mitchell, A. J., Herdt, A. D., Sienaert, P. A., Probst, M., & Binder, M. D. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050620 · Cited by 462
Obesity and cognitive decline: role of inflammation and vascular changes
Nguyen, J. C. D., Killcross, S., & Jenkins, T. A. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00375 · Cited by 440
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 424
Self-citation
Cardiovascular disease in patients with severe mental illness
Nielsen, R. E., Banner, J., & Jensen, S. E. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00463-7 · Cited by 389
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 405
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 470
Self-citation
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
Hert, M. A. F. D., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 365
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions
Ringen, P. A., Engh, J. A., Birkenaes, A. B., Dieset, I., & Andreassen, O. A. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00137 · Cited by 365
Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients
Mitchell, A. J., Vancampfort, D., Herdt, A. D., Yu, W., & Hert, M. D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs082 · Cited by 347
Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables
Vancampfort, D., Correll, C. U., Wampers, M., Sienaert, P., Mitchell, A. J., De Herdt, A., Probst, M., Scheewe, T. W., & De Hert, M. (2014) · Psychological Medicine · doi:10.1017/s0033291713002778 · Cited by 317
A systematic review of correlates of physical activity in patients with schizophrenia
Vancampfort, D., Knapen, J., Probst, M., Scheewe, T., Remans, S., & De Hert, M. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01814.x · Cited by 306
Antipsychotic drugs and obesity
Correll, C. U., Lencz, T., & Malhotra, A. K. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.010 · Cited by 315
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
Self-citation
Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects
Nguyen, T. T., Kosciolek, T., Maldonado, Y., Daly, R. E., Martin, A. S., McDonald, D., Knight, R., & Jeste, D. V. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.014 · Cited by 260
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
Maayan, L. A., & Correll, C. U. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0015 · Cited by 257
Severe Mental Illness and Cardiovascular Disease
Goldfarb, M., Binder, M. D., Detraux, J., Palo, K. E. D., Munir, H., Music, S., Piña, I. L., & Ringen, P. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.017 · Cited by 250
Humanistic burden in schizophrenia: A literature review
Millier, A., Schmidt, U. H., Angermeyer, M. C., Chauhan, D., Murthy, V., Toumi, M., & Cadi-Soussi, N. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.03.021 · Cited by 242
The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta‐analysis
Stubbs, B., Vancampfort, D., Hert, M. A. F. D., & Mitchell, A. J. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12439 · Cited by 244
The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials
Vancampfort, D., Firth, J., Correll, C. U., Solmi, M., Siskind, D., De Hert, M., Carney, R., Koyanagi, A., Carvalho, A. F., Gaughran, F., et al. (2019) · World Psychiatry · doi:10.1002/wps.20614 · Cited by 227
Mental health research priorities for Europe
Wykes, T., Haro, J. M., Belli, S. R., Obradors-Tarragó, C., Arango, C., Ayuso-Mateos, J. L., Bitter, I., Brunn, M., Chevreul, K., Demotes-Mainard, J., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00332-6 · Cited by 218
The interface of physical and mental health
Doherty, A. M., & Gaughran, F. (2014) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-014-0847-7 · Cited by 237
Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
Hert, M. A. F. D., Vancampfort, D., Correll, C. U., Mercken, V., Peuskens, J., Sweers, K., van Winkel, R., & Mitchell, A. J. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084665 · Cited by 226
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons
Fraguas, D., Correll, C. U., Merchán‐Naranjo, J., Rapado‐Castro, M., Parellada, M., Moreno, C., & Arango, C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.002 · Cited by 209
Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder
Nguyen, T. T., Kościółek, T., Eyler, L. T., Knight, R. D., & Jeste, D. V. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.01.013 · Cited by 216
Cardiovascular Risk Prediction Models for People With Severe Mental Illness: Results From the Prediction and Management of Cardiovascular Risk in People With Severe Mental Illnesses (PRIMROSE) Research Program
Osborn, D. P. J., Hardoon, S., Omar, R. Z., Holt, R. I. G., King, M., Larsen, J., Marston, L., Morris, R. W., Nazareth, I., Walters, K., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2133 · Cited by 200
Self-citation
2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee
Bueno, H., Deaton, C., Farrero, M., Forsyth, F., Braunschweig, F., Buccheri, S., Dragan, S. R., Gevaert, S., Held, C., Kurpas, D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf191 · Cited by 224
Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight Gain
Malhotra, A. K. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.191 · Cited by 187
Stratified medicine for mental disorders
Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.010 · Cited by 186
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort
Bobes, J., Arango, C., Garcia-Garcia, M., & Rejas, J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1030 · Cited by 181
Diabetes mellitus and severe mental illness: mechanisms and clinical implications
Holt, R. I. G., & Mitchell, A. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.203 · Cited by 189
Self-citation
TYPE 2 DIABETES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS OF PREVALENCE ESTIMATES AND PREDICTORS: Review: Depression and Diabetes
Vancampfort, D., Mitchell, A. J., De Hert, M., Sienaert, P., Probst, M., Buys, R., & Stubbs, B. (2015) · Depression and Anxiety · doi:10.1002/da.22387 · Cited by 171
Metabolic syndrome with the atypical antipsychotics
Pramyothin, P., & Khaodhiar, L. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833de61c · Cited by 174
Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study.
Bresee, L. C., Majumdar, S., Patten, S., & Johnson, J. A. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.016 · Cited by 187
Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades—a Danish nationwide study from 1980 to 2010
Nielsen, R. E., Uggerby, A. S., Jensen, S. O. W., & McGrath, J. J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.02.025 · Cited by 162
Association between antipsychotic medication use and diabetes
Holt, R. I. G. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1220-8 · Cited by 162
Self-citation
EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness
Rüther, T., Bobes, J., De Hert, M., Svensson, T. H., Mann, K., Batra, A., Gorwood, P., & Möller, H. J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.11.002 · Cited by 149
Self-citation
Second-generation antipsychotics and constipation: A review of the literature
Hert, M. D., Hudyana, H., Dockx, L., Bernagie, C., Sweers, K., Tack, J. F., Leucht, S., & Peuskens, J. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.03.003 · Cited by 152
Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial
Gardner-Sood, P., Lally, J., Smith, S., Atakan, Z., Ismail, K., Greenwood, K. E., Keen, A., O'Brien, C., Onagbesan, O., Fung, C., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715000562 · Cited by 140
“Cardiometabolic risk factors are common in psychosis (McEvoy et al. 2005; Leucht et al. 2007; Osborn et al. 2007; De Hert et al. 2009; Kilbourne et al. 2009).”
Background
The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment
Charlson, F., Moran, A. E., Freedman, G., Norman, R. E., Stapelberg, N. J. C., Baxter, A. J., Vos, T., & Whiteford, H. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-250 · Cited by 149
Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis
Mitchell, A. J., Lord, O., & Malone, D. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.094532 · Cited by 141
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
Vancampfort, D., Knapen, J., Probst, M., van Winkel, R., Deckx, S., Maurissen, K., Peuskens, J., & Binder, M. D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.03.011 · Cited by 134
A review of physical activity correlates in patients with bipolar disorder
Vancampfort, D., Correll, C. U., Probst, M., Sienaert, P., Wyckaert, S., De Herdt, A., Knapen, J., De Wachter, D., & De Hert, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.020 · Cited by 126
International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia
Vancampfort, D., De Hert, M., Skjerven, L. H., Gyllensten, A. L., Parker, A., Mulders, N., Nyboe, L., Spencer, F., & Probst, M. (2012) · Disability and Rehabilitation · doi:10.3109/09638288.2011.587090 · Cited by 127
The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain
He, M. X., Deng, C., & Huang, X. (2013) · CNS Drugs · doi:10.1007/s40263-013-0062-1 · Cited by 127
State anxiety, psychological stress and positive well-being responses to yoga and aerobic exercise in people with schizophrenia: a pilot study
Vancampfort, D., De Hert, M., Knapen, J., Wampers, M., Demunter, H., Deckx, S., Maurissen, K., & Probst, M. (2011) · Disability and Rehabilitation · doi:10.3109/09638288.2010.509458 · Cited by 123
Weight gain and metabolic changes during treatment with antipsychotics and antidepressants
Himmerich, H., Minkwitz, J., & Kirkby, K. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150623092031 · Cited by 122
Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study
Crawford, M., Jayakumar, S., Lemmey, S. J., Zalewska, K., Patel, M. X., Cooper, S. J., & Shiers, D. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.142521 · Cited by 124
Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews
Lindekilde, N., Scheuer, S. H., Rutters, F., Knudsen, L., Lasgaard, M., Rubin, K. H., Henriksen, J. E., Kivimäki, M., Andersen, G. S., & Pouwer, F. (2022) · Diabetologia · doi:10.1007/s00125-021-05609-x · Cited by 119
Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder
Citrome, L., Holt, R. I. G., Walker, D. J., & Hoffmann, V. P. (2011) · Clinical Drug Investigation · doi:10.2165/11589060-000000000-00000 · Cited by 116
Self-citation
Reduced antioxidant defense in early onset first-episode psychosis: a case-control study
Micó, J. A., Rojas-Corrales, M. O., Gibert‐Rahola, J., Parellada, M., Moreno, D. M., Fraguas, D., Graell, M., Gil, J., Irazusta, J., Castro‐Fornieles, J., et al. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-26 · Cited by 114
Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis
Mitchell, A. J., & Lawrence, D. M. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076950 · Cited by 113
Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: A systematic review
Verhaeghe, N., Maeseneer, J. D., Maes, L., Heeringen, C. V., & Annemans, L. (2011) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-8-28 · Cited by 109
Review: Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis
Mitchell, A. J., & Lord, O. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382056 · Cited by 108
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study
Binder, M. D., Dockx, L., Bernagie, C., Peuskens, B., Sweers, K., Leucht, S., Tack, J. F., de Straete, S. V., Wampers, M., & Peuskens, J. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-17 · Cited by 108
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management
Ventriglio, A., Gentile, A., Stella, E., & Bellomo, A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00297 · Cited by 115
Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey
Moreno, C., Nuevo, R., Chatterji, S., Verdes, E., Arango, C., & Ayuso‐Mateos, J. L. (2013) · World Psychiatry · doi:10.1002/wps.20070 · Cited by 108
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study
Binder, M. D., Correll, C. U., & Cohen, D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.029 · Cited by 107
Weight gain associated with taking psychotropic medication: An integrative review
McCloughen, A., & Foster, K. (2011) · International Journal of Mental Health Nursing · doi:10.1111/j.1447-0349.2010.00721.x · Cited by 107
Evidence-based pharmacotherapy of schizophrenia
Leucht, S., Heres, S., Kissling, W., & Davis, J. M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001380 · Cited by 104
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task Force on Treatment Guidelines for Schizophrenia (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1291839 · Cited by 102
Self-citation
Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care
Moore, S., Shiers, D., Daly, B., Mitchell, A. J., & Gaughran, F. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12431 · Cited by 107
Physical health and wellbeing of emerging and young adults with mental illness: An integrative review of international literature
McCloughen, A., Foster, K., Huws-Thomas, M. V., & Delgado, C. (2012) · International Journal of Mental Health Nursing · doi:10.1111/j.1447-0349.2011.00796.x · Cited by 105
A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps
Teasdale, S. B., Samaras, K., Wade, T., Jarman, R., & Ward, P. B. (2017) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12473 · Cited by 111
Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis
Liu, Y. K., Ling, S., Lui, L. M. W., Ceban, F., Vinberg, M., Kessing, L. V., Ho, R., Rhee, T. G., Gill, H., Cao, B., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.110 · Cited by 108
Severe mental illness: cardiovascular risk assessment and management
Polcwiartek, C., O’Gallagher, K., Friedman, D. J., Correll, C. U., Solmi, M., Jensen, S. E., & Nielsen, R. E. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae054 · Cited by 108
Importance of Early Weight Changes to Predict Long-Term Weight Gain During Psychotropic Drug Treatment
Vandenberghe, F., Gholam‐Rezaee, M., Saigí-Morgui, N., Delacrétaz, A., Choong, E., Solida-Tozzi, A., Kolly, S., Thonney, J., Gallo, S. F., Hedjal, A., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09358 · Cited by 98
Trends in standardized mortality among individuals with schizophrenia, 1993–2012: a population-based, repeated cross-sectional study
Gatov, E., Rosella, L. C., Chiu, M., & Kurdyak, P. A. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.161351 · Cited by 103
Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: A systematic review
Gurusamy, J., Gandhi, S., Dinakaran, D., Venkatasubramanian, G., & Marimuthu, P. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.06.018 · Cited by 96
Peer support for people with schizophrenia or other serious mental illness
Chien, W. T., Clifton, A., Zhao, S., & Lui, S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010880.pub2 · Cited by 95
Psychiatric disorders as risk factors for type 2 diabetes: An umbrella review of systematic reviews with and without meta-analyses
Lindekilde, N., Rutters, F., Henriksen, J. E., Lasgaard, M., Schram, M. T., Rubin, K. H., Mika Kivimaki, B., Nefs, G., & Pouwer, F. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108855 · Cited by 102
Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms
Gonçalves, P., Araújo, J. R., & Martel, F. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.008 · Cited by 99
Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?
Wildgust, H. J., & Beary, M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810384639 · Cited by 97
Cardiovascular aspects of antipsychotics
Raedler, T. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f46c9 · Cited by 89
Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
Rossom, R. C., Hooker, S. A., O’Connor, P. J., Crain, A. L., & Sperl‐Hillen, J. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.021444 · Cited by 86
Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
Krivoy, A., Onn, R., Vilner, Y., Hochman, E., Weizman, S., Paz, A., Hess, S., Sagy, R., Kamhi-Nesher, S., Kalter, E., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.11.027 · Cited by 86
Effect of Inadequate Sleep on Frequent Mental Distress
Blackwelder, A. J., Hoskins, M., & Huber, L. R. B. (2021) · Preventing Chronic Disease · doi:10.5888/pcd18.200573 · Cited by 98
The Impact of General Medical Conditions in Obsessive-Compulsive Disorder
Aguglia, A., Signorelli, M. S., Albert, U., & Maina, G. (2018) · Psychiatry Investigation · doi:10.30773/pi.2017.06.17.2 · Cited by 82

Authors: De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J.
Affiliations: KU Leuven (BE)
Imperial College London (GB)
Medizinische Hochschule Hannover (DE)
University of Southampton (GB)
Ludwig-Maximilians-Universität München (DE)
ORCID: Wood, D.
Holt, R.I.G.
Venue: European Psychiatry
Publisher: Cambridge University Press (CUP)
Published: 2009-09
Volume: 24
Issue: 6
Pages: 412-424
ISSN: 0924-9338 (ISSN-L)
1778-3585
DOI: 10.1016/j.eurpsy.2009.01.005
OpenAlex: W2154493342
Cited by: 951
References: 152
Citations by year: 2026: 27 · 2025: 32 · 2024: 37 · 2023: 61 · 2022: 42 · 2021: 64 · 2020: 59 · 2019: 62 · 2018: 46 · 2017: 44 · 2016: 69 · 2015: 63 · 2014: 71 · 2013: 66 · 2012: 65
FWCI: 42.54
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified, 3880 d)
Locations: European Psychiatry (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Lirias (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Bristol-Myers Squibb
European Society of Cardiology
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: severe mental illness, cardiovascular disease, diabetes mellitus, schizophrenia, bipolar disorder, depression, cardiovascular risk factors, antipsychotic-induced weight gain, psychotropic drugs, cardiovascular risk screening, cardiovascular disease prevention, shared care, life expectancy, coronary artery disease
MeSH terms: Bipolar Disorder, Cardiovascular Diseases, Cause of Death, Cross-Sectional Studies, Major Depressive Disorder, Diabetes Mellitus, Follow-Up Studies, Humans, Mass Screening, Obesity, Psychotic Disorders, Psychotropic Drugs, Risk Factors, Schizophrenia, Societies, Medical, Comorbidity, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks